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Smary Chromosomal aberrations in human gliomas are principally numerical. In tumours of low malig-
nancy, karyotypes are frequently normal, but occasionally an excess of chromosome 7 and a loss of sex
chromosome are observed. In highly malignant tumours, the most frequent aberrations are gain of
chromosome 7, loss ofchromosome 10 and less frequently losses or deletions of chromosomes 9, 22, 6, 13 and
14 or gains of chromosomes 19 and 20. To understand the meaning of these chromosome imblances, the
relationships between chromosome abnormalities and metabolic disturbances were studied. The losses or
deletions observed affected principally chromosomes carrying genes encoding enzymes involved in punne
metabolism. The activities of ten enzymes were measured: adenosine kinase, adenine phosphoribosyltrans-
ferase, adenylate kinase, methylthioadenosine phosphorylase, hypoxanthine phosphoribosyltransferase,
adenylosuccinate lyase, inosine monophosphate dehydrogenase, adenosine deaminase, nuckoside phos-
phorylase and adenosine monophosphate deaminase. In paralkle, two enzymes involved in pyrimidine
metabolism, thymidine kinase and thymidylate synthase (TS), were studied. The activities of all these enzymes
were measured on samples from 30 human primary glial tumours with low or high malignancy, six xenog-
rafted tumours at different passages, four portions of normal brain tissue and four non-gal brain neoplasms.
As suggested by cytogenetic data, the enzymatic results showed a relatively low activity of puine metabolism
in ghal tumours when compared with normal brain and non-glial brain neoplasms. Considering the two
enzymes involved in pyrimidine metabolism, only T'S had higher activity in glial tumours of high malignancy
than in normal brain. In comparison with normal brain, the balanc between salvage and de novo pathways
changes in gliomas, and even more in grafted tumours, in favour of de novo synthesis. The relation between
chromosomes and metabolic imbalancs does not correspond to a simple gene dosage effect in these tumours.
These data suggest that the dcrease of adenosine metabolism ocus before chromosomal aberrations appear,
since it is observed in tumours of low malignancy when most karyotypes are still normal, and that the de novo
pathway increases with tumour progression.
Glial tumours are the most common primary tumours in the
human central nervous system. These neoplasms form a
heterogeneous group, composed of several histological sub-
types, with different degrees of malignancy. Glioblastoma
multiforme and high-grade astrocytomas represent more than
half the cases (James et al., 1988; Yung et al., 1989; Venter &
Thomas, 1991). Despite many attempts to characterise these
tumours by biochemical, cytogenetic, immunochemical and
molecular approaches, progress in therapy is limited and the
prognosis for patients remains poor.
Cytogenetic analyses have been extensively performed on
human gliomas (Rey et al., 1983, 1987a, b; Bigner et al.,
1986, 1988, 1990; Heim et al., 1989; Jenkins et al., 1989;
Thiel et al., 1992). In tumours of low malignancy, the
karyotype is frequently normal or may exhibit a loss of sex
chromosome and a gain ofchromosome 7. These two abnor-
malities, being observed in normal cells in culture (Rey et al.,
1987a; Heim et al., 1*69; Thiel et al., 1992), may not neces-
sarily characterise a malignant condition. Hence, no specific
chromosomal anomaly may occur in such tumours. In highly
malignant tumours, by contrast, karyotypes tend to become
polyploid with an accumulation of anomalies, among which
gain of chromosome 7 and loss of chromosome 10 are the
most frequent. Other abnormalities, such as losses or dele-
tions of chromosomes 9, 22, 6, 13 and 14 or gains of
chromosomes 19 and 20, may be observed also, but less
frequently (Rey et al., 1987b; Bigner et al., 1988, 1990;
Jenkins et al., 1989). In addition, a large proportion ofhighly
malignant gliomas have double minute chromosomes (Bigner
et al., 1986, 1990; Thiel et al., 1992).
We postulate that these recurrent chromosomal imbalances
could be related to metabolic disturbances, as in human
colorectal adenocarcinomas, in which activities of de novo
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and salvage pathways for pyrimidine synthesis have been
related to cytogenetic anomalies (Luccioni et al., 1988; Bar-
dot et al., 1991; Bravard et al., 1991). In brain tumours,
cytogenetic anomalies (especially losses) tend to involve
chromosomes carrying genes encoding enzymes of adenine
metabolism: AKI and AX2 (adenylate kinase) and MTAP
(methylthioadenosine phosphorylase) on chromosome 9,
ADK (adenosine kinase) and ATPase (ATP synthetase
mitochondrial) on chromosome 10, ADSL (adenylosuccinate
lyase) on chromosome 22, NP (purine nucleoside phos-
phorylase) on chromosome 14 and ADA (adenosine
deaminase) on chromosome 20 (HMG 10, 1989). This led us
to search for a possible modification of adenine metabolism
in these tumours by assaying the activities of ten enzymes
involved in de novo salvage and catabolism pathways: ADK
(EC 2.7.1.20), AK (EC 2.7.4.3), MTAP (EC 2.4.2.28), APRT
(adenine phosphoribosyltransferase, EC 2.4.2.7), HPRT
(hypoxanthine phosphoribosyltransferase, EC 2.4.2.8), ADSL
(EC 4.3.2.2), IMPDH (inosine monophosphate dehydro-
genase, EC 1.1.1.205), NP (EC 2.4.2.1), ADA (EC 3.5.4.4)
and AMPD (adenosine monophosphate deaminase, EC
3.5.4.6). The relationship of these enzymes in the general
pathway of purine metabolism is shown in Figure 1. In
parallel, two enzymes involved in pyrimidine synthesis, TK
(thymidine kinase, EC 2.7.1.21) and TS (thymidylate syn-
thase, EC 2.1.1.45), were studied.
Since tumours grafted in nude mice are widely used and
represent an interesting source of partially purified tumour
tissue, we also studied six human gliomas growing as nude
mouse xenografts.
Materiasd and methods
Chemicals
All chemicals were purchased from Sigma (St Louis, MO,
USA). [8-'4Cjadenosine, [8-'4Cladenine, [8-4C]inosine mono-
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phosphate and [5-3H]deoxyuridine monophosphate (dUMP)
were purchased from Amersham (Les Ulis, France), ['4C-
thymidine from Oris (Commissariat a l'Energie Atomique,
Gif sur Yvette, France) and [8-"'C5'deoxy-5'-methyl-
thioadenosine from Moravek Biochemicals (Brea, USA).
Origin and conservation oftumour samples
Enzyme assays for purine and pyrimidine metabolism were
performed on 30 glial tumours from adult patients and on
four samples of normal brain, taken far from tumour tissue.
In paralel, these enzymes were also studied in four diverse
benign or malignant non-glal human brain tumours (one
angioma, one meningioma, one lymphoma and one meta-
stasis ofcarcinoma). All samples were obtained after surgical
resection at the Pitie Salpetriere Hospital (Paris, France).
Glial tumours were classified as oflow malignancy (11 cases)
in the case of histological grades I and H astrocytomas and
oligodendrogliomas and as highly malignant (19 patients,
including five who had relapsed) in the case of histological
grades III and IV astrocytomas, oligodendrogliomas, ana-
plastic tumours and glioblastoma multiforme (GBM).
Tissue samples were taken in the proliferating region ofthe
tumours: one part for cytogenetic studies, one part for trans-
plantation into nude mice and one part frozen in liquid
nitrogen for further enzymatic studies. In the case of six
highly malignant glial tumours, studies were performed on
tumours grafted in nude mice, from passage 1 to passage
10.
Preparation ofhomogenates
Samples were homogenised in Tris-HCl buffer 50mM, suc-
rose 250mM, Triton X-100 0.1%, pH 7.5 (1/1, w/v).
Homogenates were then centrifuged at 20,000 g for 1 h and
supernatants were stored as aliquots at -80-C for all further
enzymatic measurements.
Enzyme assays
Purine metabolism, including the ten enzymes studied, is
depicted schematically in Figure 1. The activities of ADK,
APRT, AK, HPRT, ADSL, ADA, NP and AMPD were
determined according to methods to be described elsewhere.
MTAP activity was determined by measuring the formation
of adenine from [8-'4Cmethylthioadenosine, according to a
method described by Kamatani and Carson (1980). The final
concentrations of the reaction mixture were 100mM phos-
phate buffer, pH 7.4, 35 mM potassium hydrogen phosphate,
0.05 mM [8-'4CJ5'-deoxy-5'-methylthioadenosine (4.6 Ci
mol-'). The reaction mixture was incubated for 45 min at
37C and the reaction stopped by heating at 100lC for 2 min.
Samples were then centrifuged at 15,000g for 20 min, before
quantification of products and substrates by a high-
performance liquid chromatographic (HPLC) method. The
separation was effected on a reversed-phase silica column, Cl,
Novapak (Waters). The mobie phase was composed of
15.5% methanol and 2% 500mM phosphate buffer with an
apparent pH of 6. The isocratic elution was run at a flow
rate of 1 mlmin'-. TK activity (total activity) was deter-
mined by a radiochemical assay (Bardot et al., 1991). TS
activity was determined by measuring the formation of
tritiated water from [5-3H]dUMP (Bardot et al., 1991).
For each enzyme assay, linearity with time and protein
content was verified. Liver extracts from newborn rats were
run in parallel as standard and all values were read against a
blank without cellular extract. All assays were performed in
duplicate and results were normalised to the protein content
for each sample. Protein content was estimated using a Bio-
Rad kit (Richmond, CA, USA) with albumin as standard.
All enzymatic assays were adapted from previously published
methods, to use microquantities of tumour samples.
The Mann-Whitney U-test was used for comparing the
different groups of samples: primary tumours versus normal
brain tissue, tumours of low grade versus tumours of high
grade and grafted tumours versus the corresponding primary
tumours.
Cytogenetic studies
For direct karyotyping, fresh human tumours were minced
with scissors and seeded into medium F12 (Gibco) containing
20% fetal calf serum and epidermal growth factor (Sigma)
(0.03 mg I'). Metaphases were obtained after 1-3 weeks'
culture.
Athymic 5-week-old female nude mice (nu/nu, Swiss genetic
background) were transplanted with pieces of approximately214 V. BARDOT et al.
3 mm in diameter into the right flanks. Between 1 and 4
animals were transplanted with each tumour, and further
passages were performed in the same way in 4-5 animals.
After tumour transplantation, mice were observed for up to 5
months for tumour appearance in the right flank. For
karyotyping, short-term cultures were performed 3-15 days
after dissociation of the grafted tumours.
Hypotonic shock (human plasma diluted 1:6 in distilled
water), fixation by Carnoy with and without chloroform and
R-banding were performed as previously described (Dutril-
laux & Couturier, 1981).
Resuls
Cytogenetics ofglial twnours
Among the 30 tumours (11 of low and 19 of high malig-
nancy), no metaphases were obtained in 11 cases (six of low-
and five of high-grade malignancy). In six cases (five of low
and one of high malignancy), karyotypes were normal.
Finally, in 13 cases (one of low and 12 of high malignancy,
including four recurrent tumours), there were generally few
chromosome rearrangements, but recurrent imbalances.
However, recurrent tumours, which had all been treated by
radiotherapy, had more chromosomal rearrangements.
Details of their chromosome alterations are given in Pruchon
et al. (in press). The results are summarised in Table I, and
Figure 2 gives one example (case N.G.) in which karyotypes
were obtained from both primary tumour and xenograft. The
most frequent imbalances observed were, in decreasing order
ofdeficiencies: 10 (12/13), 9p (4/13), 16 and 22 (3/13), 14, 17q
and 18 (1/13); and for gains 7 (9/13), lp and 20 (3/13). These
results are in agreement with previously published data
indicating the relationship between abnormal karyotypes and
tumour progression.
Nucleotide metabolism in primary glial twnours
Purine metabolism The mean activities of the ten enzymes
involved in adenine metabolism, calculated from 16-30
cases, are shown in Figure 3 and compared with those
measured in normal brain. As indicated by the large standard
deviations, there were high inter-tumoral variations in
activities of all the enzymes studied.
For the ten enzymes studied, mean activities compared
with those measured in normal brain (100%) were very
similar for ADK, MTAP and ADSL, lower for APRT
(89%), AK (62%) and ADA (56%), and much lower for
HPRT (35%), slightly higher for NP (126%) and much
higher for AMPD (182%) and IMPDH (193%). However,
differences were not statistically significant, except for HPRT
(P = 0.04).
Pyrimidine metabolism The mean activities of the two
enzymes (TK and TS) involved in pyrimidine metabolism,
measured on 30 primary glial tumours, are shown in Figure
3, and compared with activities in normal brain. Mean
activities, especially for TS, were higher in tumours than in
normal brain, however differences were not statistically
significant.
Nucleotide metabolism in non-glial intracranial tunours
Purine metabolism Only six enzymes involved in adenine
metabolism were studied in the four non-glial intracranial
tumours and compared with activities observed in glial
tumours. These results are shown in Figure 4. In comparison
with these non-glial intracranial tumours, meningiomas char-
acterised by a high MTAP activity and lymphoma by high
APRT, ADA and NP activities, gliomas had a different
metabolic profile ofenzymes involved in adenine metabolism,
except when compared with the angioma, the most benign of
non-glial tumours.
Pyrimidine metabolism The activities represented in Figure 4
were compared with those measured in all primary glial
tumours. In comparison with the non-glial intracranial
tumours (angioma excepted), gliomas had a low TK activity
and the lowest TK/TS ratio.
Nucleotide metabolism in human glial tumours as afunction of
grade
Purine metabolism Among the 30 glial tumours studied, 11
were of low and 19 of high malignancy. The comparison of
the two groups is summarised in Figure 5, which also gives
the average values of enzyme activities in normal brain. In
tumours of low malignancy, average activities of enzymes
involved in purine metabolism were similar to normal brain
for ADK, APRT, MTAP, ADSL, NP, AMPD and AK and
lower for HPRT and ADA, but differences were not statis-
tically significant. Considering tumours of high malignancy,
enzyme activities were either similar to those measured in
gliomas of low malignancy or seemed to evolve with tumour
grades for APRT (P = 0.06). The only significant change was
for NP (P=0.01).
Pyrimidine metabolism The results are summarised in Figure
5. TK activity was, in both low- and high-grade tumours, of
the same order of magnitude as in normal brain. However
TS activity, which was similar in low-grade gliomas and in
normal brain, was higher in tumours with high malignancy.
The average TK/TS ratio was similar in tumours of low
malignancy (5.9) and in normal brain (4.3). This ratio
decreased sharply in highly malignant tumours (1.2).
Nucleotide metabolism in glial tumours xenografts
The six glial tumours successfully grafted in nude mice were
either gliomas of high grade or recurrent tumours. The
enzyme activities measured for these six tumours before
xenografting were representative of the mean activities
measured in all the glial tumours ofhigh malignancy studied.
Purine metabolism From the six glial tumours grafted,
assays were performed on a total of 18 samples, i.e. 2-4
samples per case obtained from the first to the tenth passage.
Inter-tumoral variations were as high as in primary tumours,
as shown by the large s.d. in Figure 6, and there were only
slight variations from passage to passage for grafted tumours
(data not shown). All enzyme activities were either similar to
those measured in the corresponding primary gliomas or
increased for ADSL (P=0.01), MTAP (P<0.01) and
IMPDH (P<0.01).
Pyrimidine metabolism The two enzymes involved in
pyrimidine metabolism had increased activities in xenografts,
but the increase was more marked for TS. Large inter-
tumoral variations for the two enzymes TK and TS were
observed in grafted tumours, and also from passage to pas-
sage for the same tumour (data not shown). The increase
between primary and grafted tumours was significant for
both TK (P<0.01) and TS (P = 0.01), as shown in Figure 6.
Grafted tumours were characterised by a very low TK/TS
ratio (0.2).
Comparison between enzyme activities andcytogenetic data
As shown in Table I, except for chromosomes lp and 20
(respectively carrying the genes for AMPD and ADA), the
chromosomes carrying the genes coding for the enzymes of
purine metabolism were deficient either frequently (10 for
ADK, 9p for MTAP, 22 for ADSL) or occasionally (9q for
AK, 14 for NP and 16 for APRT). The activities of these
enzymes in glial tumours were similar to those observed in
normal brain. Considering the proliferative character of
malignant cells, this indicates a low activity of this
metabolism, as suggested by cytogenetic data. However, the
relationship between deletion and low enzyme activities orCHROMOSOMAL ABERRATIONS IN GLIOMAS
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Figwe 3 Enzymes involved in purine and pyrimidine
metabolism: activities (mean and standard deviation) in normal
brain (0) and in primary human glial tumours (-). The
activities are expressed in 10-'molh-'mg-' protein for ADK,
APRT, MTAP and HPRT, in 10-7molh-'mg-' protein for
ADSL, ADA and AMPD, in 10-6 mol h' mg-' protein for NP,
in IO-I mol h- mg- protein for AK, in 10-' mol h-' mg- pro-
tein for TK and in 10-`molh-'mg-' for TS. HPRT was
measured in normal brain for only two samples.
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Fugue 4 Enzymes involved in purine and pyrimidine meta-
bolism: activities (mean and standard deviation) in human glial
tumours and in non-glial brain neoplasms. The activities are
expressed in the same units as for Figure 3.
Above 25
Fugwe 2 Karyotypes from patient N.G. a, 49, XY, del(l)
(p21p3l), + 7, del(9) (p2), -10, + 20, + 21, + mar from fresh
tumour. b, From xenografted tumour, exhibiting the same
anomalies after endoreduplication. Losses of chromosomes 10
and 9p and gains of chromosomes 7 and 20 are frequent events in
malignant gliomas.
between chromosome gains and high enzyme activities was
not direct when tumours were considered case by case (data
not shown), which means that this cannot be explained by a
simple gene dosage effect. Considering TK and TS activities,
the relation with chromosome number (17q for TK and 18p
for TS) was also indirect; one primary tumour had a
monosomy 18 and its TS activity was not the lowest.
Disc-ssiom
The characteristic chromosomal anomalies occurring in
human glial tumours are documented by the study of more
than 100 cases (Rey et al., 1983, 1987a, b; Bigner et al., 1986,
1988, 1990; Heim et al., 1989; Jenkins et al., 1989; Thiel et
al., 1992). These anomalies are essentially numerical. Specific
chromosomal rearrangements are not evident, but some
chromosomes (1, 6 and 9) are recurrently affected. Their
ADK AK HPRT IMPDH NP TK
APRT MTAP ADSL ADA AMPD TS
Fige 5 Enzyme activities of purine and pyrimidine metabolism
(mean and standard deviation) in human glial tumours as a
function of tumour grade
- comparison with normal brain. The
activities are expressed in the same units as for Figure 3.
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Figue 6 Enzyme activities of purine and pyrimidine meta-
bolisms (mean and standard deviation) in glial tumours, both
primary and grafted in nude mice - comparison with normal
brain. The activities are expressed in the same units as for Figure
3.
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rearrangements generally lead to deletions of lq, 6q and 9p
arms. In addition, chromosome 7 is very often in excess,
whereas losses affect whole chromosomes 10 and less fre-
quently 22 and the sex chromosomes (late replicating X or
Y). In an attempt to elucidate the meaning of chromosome
imblances in solid tumours, it was proposed that a relation-
ship might exist with some metabolic modifications of cancer
cells. For instance, the recurrent gains in endometrial
adenocarcinoma affected chromosomes carrying genes for
glycolysis (Couturier et al., 1988), and in colorectal adenocar-
cinomas gains and losses affect chromosomes carrying genes
encoding, respectively, the salvag and the de novo pathways
of pyrimidine nucleotides (Dutrillaux & Mukris, 1986; Luc-
cioni et al., 1988; Bardot et al., 1991). In colorectal adenocar-
cinoma, this hypothesis was tested by the study of enzymes
involved in pyrimidine metabolism in both primary and
grafted tumours, and a good correlation between chromo-
some imbalances and enzyme activities was demonstrated,
especially in grafted tumours which are devoid of human
non-neoplastic cells. The metabolism of human gliomas re-
main largely unknown except for energy metabolism. The
activities of many enzymes involved in glycolysis (Lowry et
al., 1983; Marzatico et al., 1986) and the quantification of
high-energy phosphate compounds (Lowry et al., 1977) sug-
gest that gliomas have lower metabolic rates than normal
brain tissue. Despite contradictory previous results (Lowry et
al., 1983; Mangiardi & Yodice, 1990, Pillwein et al., 1990),
the low levels of guanylate and adenylate pools in human
gliomas were recently confirmed by Pillwein et al. (1990).
These authors also studid four enzymes involved in purine
metabolism, three in the salvage pathway (HPRT, APRT,
ADK) and one in the de novo synthesis (IMPDH). Only
IMPDH activity was increased. Their results suggest a
relatively low activity of purine metabolism in human glio-
bUastomas. Since cytogenetic data had demonstrated
deficiencies of chromosomes 9, 10 and 22, carrying genes for
MTAP and AK, ADK and ADSL respectively, it was of
interest to study the same tumours by both cytogenetic and
metabolic approaches.
In gliomas there are large variations in the activities of
enzymes involved in both purine and pyrimidine metabolism.
Tlhis is in agreement with the well-documented heterogeneity
of these neoplasms in terms of morphological and immuno-
chemical properties and metabolic behaviour (Bigner et al.,
1981; Paulus & Pfeiffer, 1989; Shapiro, 1986). Despite these
variations, our results show that glial tumours exhibit a
characteristic profile of purine and pyrimidine metabolism
compared with non-glial neoplasms (Figure 4).
This study of 11 glial tumours with low malignancy
revealed an abnormal and unbalanced karyotype in one case
only. In the others, the karyotypes were normal (five cases)
or no cell growth could be obtained (six cases). The assays
performed on these samples show that the levels of most
enzymes involved in purine and pyrimidine metabolism are
similar in normal brain and in gliomas with low malignancy,
as shown in Figure 5. For ADA and HPRT, activities are
lower in malignant cells. Among the 19 tumours with high
malignancy, 12 had unbalaned karyotypes, one had normal
chromosomes, one had only balanced rearrangements and no
cell growth was obtained in five cases. The detected
chromosome imbalances are in agreement with published
data (Bigner et al., 1988, Rey et al., 1983, 1987), except that
we did not observe loss of sex chromosomes. For the two
enzymes of pyrimidine synthesis, only TS activity is higher in
tumours with high malignancy than in normal brain. It is
noteworthy that the loss of chromosome segments occuring
in tumours of high malignancy, by comparison with tumours
of low grade, cormsponds to slightly lower activities.
Differences were too small to be statstically significant how-
ever, and the s.d. was large. The relationship between
metabolic modifictions and chromosomal aberrations is far
from direct and does not correspond to a gene dosage effect.
It is even possible that the relative decrease in purine
metabolism occurs before chromosome imblans, since it is
observed at low malignancy, when most karyotypes are still
normal.
Considering enzyme activities in purine metabolism, our
results suggest a low rate of ATP synthesis, enzymes involved
in the synthesis of adenylate pools such as ADK, APRT,
AK, MTAP and ADSL being similar in gliomas and in
normal brain. In contrast, enzymes involved in catabolism,
such as NP and AMPD, are slightly more active in gliomas.
Such findings are unexpected in malignant highly prolifera-
tive cells, which supposedly need a large ATP supply. How-
ever, activities of enzymes involved in pyrimidine metabolism
are similar or higher in gliomas than in normal brain. This
indicates that the tumour samples were not degraded and
points to the importance of the relatively low pure
metabolism.
The balance between de novo and salvage pathways also
appears to be altered in gliomas. In normal brain, salvage
pathway for adenylates is low (APRT, ADK and MTAP),
whereas that for guanylates is high (HPRT). APRT, ADK
and MTAP activities are low in gliomas, on average, suggest-
ing a possible decrease in the activity of the adenylate salvage
pathway. For guanylates, HPRT activity decreases, whereas
that of IMPDH, involved in the de novo pathway, slightly
increases, which is in agreement with previous data showing
that IMPDH activity is an indicator of growth rate (Jackson
& Weber, 1975). These results also suggest a low activity of
the salvage pathway, which contrasts with the hypothesis
that an increased salvage/de novo pathway ratio characterises
malignant cells (Natsumeda et al., 1984). The same results
are obtained for the thymidylate pathways, since the mean
TK/TS ratio is decreased in tumours of high malignancy
compared with normal brain.
The comparison between enzyme activities in primary and
xenografted tumours deserves some comment (Figure 6). A
previous study on colorectal adenocarcinoma (Lefrangois et
al., 1989) demonstrated the maintenance of chromosomal
characteristics from fresh to xenografted tumours. The same
observation was made in those cases in this study which
could be studied before and after xenografting (not shown).
As regards enzyme activities, similar characteristics could be
found in fresh and xenografted colorectal cancers (Luccioni
et al., 1988; Bardot et al., 1991), although some differences
existed. In this study, no significant changes were observed
for five enzymes: ADK, AK, ADA, NP and AMPD. This
suggests either that primary tumours are almost completely
formed of malignant cells or that the presence of non-
malignant ceUs does not alter the overall activity of these
enzymes. However, the activity of several other enzymes
(ADSL, MTAP and IMPDH) involved in purine metabolsm,
and TK, but more particularly TS, involved in pyrimidine
metabolism, is increased in xenografts, which favours the
second possibility. It is also noteworthy that, after xeno-
grafting, the imbalance between de novo and salvage path-
ways is amplified, de novo pathways increasing preferentially
in both purine and pyrimidine metabolism. These differences
could be partially explained by a higher tumour growth rate
in nude mice, and by the fact that tumour transplantations
were conducted on the right flank of the mice and not
intracerebrally.
In conclusion, cytogenetic data are well correlated with
tumour stage, low-grade malignancies having normal or
almost normal karyotypes, whereas high-grade malignancies
have more anomalies, resulting in imbalances, principally
chromosome losses or deletions. These deletions affect a
number of genes involved in adenine metabolism, which is
found to be of low activity. It is noteworthy that in highly
malignant tumours, which are proliferative, the rate of
adenine metabolism is not increased, in spite of their need of
DNA precursors. This could result in a low ATP formation,
which is in agreement with published data (Pillwein et al.,
1990). Although deletions and low metabolic rates appear to
be related, their relationship is not direct, and it is not the
result ofa simple gene dosage effect. That low-grade tumours
have metabolic disturbances but generally no chromosome218 V. BARDOT et al.
imbalance suggests that metabolic changes occur before
chromosomal alterations during tumour progression.
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